Get In Touch

Pheochromocytoma is an efficient catecholamine-secreting tumor of the adrenal gland medulla. Catecholamines include norepinephrine, epinephrine, and their derivatives. Symptoms of pheochromocytoma include flank skin, elevated heart rate, elevated blood pressure, anxiety, sweating, headache, and weight loss. Within normal limits, norepinephrine and epinephrine hormones are responsible for regulating the blood pressure and heart rate. Excess production of catecholamine due to pheochromocytoma is a reason for high blood pressure with life-threatening and potentially serious difficulties such as stroke and heart attack. Pheochromocytoma occurs most frequently in adults aged between 30 and 60 years. Pheochromocytomas are not life-threatening mostly, but have 10% chances of being cancerous. High blood pressure is the most significant symptom; however, excessive sweating, light-headedness, a fast and pounding pulse when standing, severe headache, rapid breathing, and other symptoms may also occur.

The pheochromocytoma market can be segmented based on diagnosis, treatment, and region. Based on diagnosis, the market can be segmented into laboratory tests, imaging tests, and genetic testing. Laboratory tests include 24-hour urine test and blood test. These tests help in measuring the levels of noradrenaline, adrenaline, and byproducts of these hormones in the patient’s body. Furthermore, imaging tests include computed tomography (CT) scan, magnetic resonance imaging (MRI), M-iodobenzylguanidine (MIBG) imaging, and positron emission tomography (PET). Genetic testing includes profiles of plasma catecholamine metabolites in patients with hereditary pheochromocytoma. Based on treatment, the pheochromocytoma market has been segmented into medications and surgery. Medications include Beta blockers that decrease the heart rate and reduce the blood pressure and antihypertensive drugs that lower the blood pressure. Moreover, surgery includes adrenalectomy, which is surgical removal of one or both the adrenal glands.

Based on geography, the global pheochromocytoma market can be segmented into four major regions: North America, Europe, Asia Pacific, and Rest of World. North America dominates the global pheochromocytoma market, followed by Europe. Key factors driving the market in these two regions are growing awareness about malignant effects of tumor among the people and availability of sophisticated and technologically advanced treatment options in these regions. According to Clinical Key, a health care website by Elsevier, Inc., the prevalence of tumor is estimated to be around 2 cases per 100,000 individuals in the U.S. every year. Around 5% of adrenal incidentalomas are pheochromocytomas. Studies have also shown that about 25% of them are hereditary. Hence, increasing expertise in gene therapy may also help in curbing the cancer growth. Advancements in the diagnosis and treatment of cancer are likely to add to product offerings in the near future. The prevalence of cancer is increasing in developing countries. Thus, cost-effective treatment options are likely to witness high demand in these countries. According to an article published by Progenics Pharmaceuticals Inc., the number of patients in the U.S. is around 4000 to 6000 currently, with less than 1000 new cases diagnosed in 2016. Additionally, unhealthy lifestyle habits such as smoking and drinking are contributing to growth of the pheochromocytoma market in North America. Asia Pacific is one of the most promising markets for pheochromocytoma, as the region is developing rapidly. Furthermore, presence of emerging economies and easy penetration of the market in developing countries in Asia would drive the pheochromocytoma market in Asia Pacific in the near future.

Several pharmaceutical companies are currently developing therapeutic treatments to reduce the malignant effects of the pheochromocytoma. Some of the top players operating in the global pheochromocytoma market are Exelixis, Inc., MediaPharma s.r.l., Pfizer Inc., Progenics Pharmaceuticals, Inc., and Valeant Pharmaceuticals International, Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Pheochromocytoma Market

Pre Book